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Introduction
Over the past few decades, surgery for breast carcinoma has
evolved from radical mastectomy to breast conservation. At
present, axillary lymph node dissection (ALND) remains the
standard of care for surgical management of all patients with
invasive breast carcinoma, as it provides precise staging and
excellent local control.1,2 However, routine ALND exposes
a large number of patients, particularly those with node-
negative breast cancer, to unnecessary perioperative risk
and long-term morbidity in the form of neuropathies, lym-
phoedema and shoulder syndrome.3 Contrary to the Halste-
Sentinel Lymph Node Biopsy Assessment Using
Intraoperative Imprint Cytology in Breast Cancer
Patients: Results of a Validation Study
dian concept of breast cancer, the Fisherian hypothesis pos-
tulates that breast cancer is a systemic disease and also ques-
tions the validity of routine axillary dissection in the quest for
breast cancer cure.4
The concept of sentinel lymph node biopsy (SLNB) emerged
in the early 1970s to obviate the need for routine lymphadenec-
tomy and to identify the subset of patients at risk of regional
and systemic spread. The initial work on sentinel nodes was
performed in malignant melanoma patients;5 with the en-
couraging results, SLNB was tried in other solid tumours,6
including breast cancer.7–9 There has been an exponential in-
crease in the literature related to SLNB in breast cancer, and
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most Western centres have started advanced work to evalu-
ate the therapeutic role of SLNB in early breast cancer pa-
tients.7–9 More recently, there have also been reports of SLNB
in locally advanced breast cancer (LABC).10,11
There is, however, a paucity of literature on SLNB from
developing countries. There is a need to address certain issues
relevant to breast cancer patients in developing countries,
including standardization and validation of the SLNB tech-
nique, the role of SLNB in LABC, and finding cheaper and re-
liable alternatives to frozen-section and gamma-probe meth-
ods. This study was undertaken to address these issues.
Patients and methods
This prospective validation study, undertaken in a tertiary
care cancer centre (Institute Rotary Cancer Hospital, All
India Institute of Medical Sciences), included 76 women
with operable breast carcinoma (Stage I, II or III) between
January 2000 and December 2002. Six patients with LABC
also received neoadjuvant chemotherapy. Clinical exami-
nation and mammogram were performed for all patients
to assess the primary tumour and axillary node status.
Informed consent was obtained from all patients. Breast
conservation surgery was performed in 22 and modified radi-
cal mastectomy in 54 patients. Level I, II or III ALND was
performed in all patients after SLNB evaluation.
SLNB technique
A standard blue-dye method was used as described by Giu-
liano et al.12 Isosulfan blue dye (4 mL of 1%; Sigma-Aldrich,
Milwaukee, WI, USA) was injected peritumourally at the 12, 3,
6 and 9 o’clock positions. Centripetal massage was applied
around the injection site for 2 to 3 minutes to facilitate the
diffusion of dye into the lymphatics. The axilla was explored
through an oblique 5 cm incision behind the anterior axillary
fold 5 minutes after the injection of dye. Meticulous dissection
was performed in the subcutaneous plane to identify the blue
lymph vessel. Once identified, the blue lymph vessel was traced
to the blue node distally and primary tumour proximally. The
first draining blue node was labelled the sentinel node and
removed for analysis. Further exploration was performed for
any second-echelon nodes before proceeding to definitive
surgery, including complete axillary dissection irrespective of
the outcome of SLNB.
Intraoperative assessment of SLNB
Intraoperative imprint cytology (IIC) assessment of the SLN
was performed instead of standard frozen sections. After ob-
taining imprint smears, the SLN was submitted separately for
histopathological examination. The final histopathology re-
port was taken as a gold standard for analysing the accuracy of
IIC results.
The sentinel node was sectioned at two levels. Touch im-
print smears were taken from all four cut surfaces. The smears
were air-dried for 5–6 minutes and then stained using a rapid
Jenner-Geimsa technique: the slide was stained with Jenner
stain for 2 minutes and counterstained with Geimsa for 7
minutes. Two oncopathologists evaluated the slides inde-
pendently. All sections were scanned for metastatic tumour
deposits and were reported as positive or negative for malig-
nancy (Figure).
The identification rate of SLN, sensitivity, specificity and
accuracy of SLNB and IIC, with final histopathology as gold
standard, were calculated in a standard fashion. In addition,
the negative predictive value of SLNB was calculated.
Results
Sixty-one patients had stage I or II breast cancer and 15 had
stage III breast cancer according to pTNM. The mean tumour
size was 3 cm (1–7 cm). The mean age of patients was 50.6 years
(range, 30–68 years). The tumour was located in the upper
outer quadrant in 48 patients, lower outer quadrant in eight,
upper inner quadrant in eight and lower inner quadrant in
three. The tumour was central in six patients and multicentric
in three.
SLNB
The SLN (blue node) was identified in 69 of 76 patients, with
an overall identification rate of 90.8%. With increasing ex-
Figure. Touch imprint of an axillary sentinel lymph node showing a
cluster of large tumour cells against a background of lymphocytes
(original magnification ×1,000).
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perience, the rate of identification increased to 96% in the last
50 cases. The median time taken for SLN identification was 12
minutes (range, 8–20 minutes). A total of 99 SLNs were iden-
tified in the 69 patients. The mean number of SLNs per patient
was 1.43 (range, 1–4). In 62 patients, the first draining node
was found at level I, while six patients had an SLN at level II.
One patient had a positive intramammary SLN away from
the axillary basin. Sentinel node identification could correctly
predict the nodal status of 63 of the 69 patients evaluated, with
an accuracy of 91.3%. The overall sensitivity, specificity and
negative predictive value of SLNB in predicting axillary node
status were 84.2%, 100% and 83.4%, respectively (Table). The
SLN was the only node involved in 12 of the 32 cases with
positive axillary nodes. Among the 15 LABC patients, the SLN
was identified in 11 (73.3%), and it was truly representative of
remaining axillary node status in 10 patients (66.7%).
The average number of nodes harvested from each patient
at ALND was 17 (range, 7–33), and the mean number of posi-
tive nodes was three (range, 1–28) in 32 patients with nodal
positivity. Extranodal spread was seen in only one patient.
Intraoperative imprint cytology
The SLNs from 69 patients were analysed using the imprint
cytology technique. In the final histopathology assessment,
SLNs showed metastases in 32 of 69 patients and IIC correctly
identified 31 of these 32 positive patients. There was only one
false-negative report on IIC and all 37 patients with a negative
SLN on final histopathology were accurately diagnosed using
IIC. The average reporting time for IIC was 15 minutes. The
overall sensitivity, specificity and accuracy of IIC were 96.9%,
100% and 98.6%, respectively. The overall accuracy of SLNB
in combination with IIC in predicting axillary node status
was 89.9%.
Discussion
Traditionally, surgery plays a major role in the management of
breast cancer, and axillary dissection is considered an integral
part of surgical management. Recently, however, its curative
role has been questioned, and less invasive methods such as
SLNB are being used to stage the disease accurately. The basis
for this paradigm shift in the management of the axilla was the
questionable therapeutic role of axillary dissection in node-
negative patients and its attendant morbidity in 30–40% of
patients.8,13,14
With the standardization of technique and encouraging
results obtained in the field of skin and penile cancer,5,15 SLNB
has been studied extensively in early breast cancer patients in
the West. The overall trend seems to be shifting towards
conservative axillary dissection, as happened with breast con-
servation surgery in the 1980s. However, the spectrum of
disease is different in developing countries and, in the absence
of proper guidelines, SLNB can be misused, leading to inap-
propriate and unscientific application of the technique. The
issues that need to be studied in developing countries are the
technique and validation of the SLNB procedure, the role of
SLNB in LABC patients, and finding reliable and less expen-
sive alternatives to frozen-section and gamma-probe methods.
Two techniques of SLNB are described in the literature, the
blue-dye method and the radiocolloid method (gamma probe).
In 1993, Krag et al reported an 82% success rate in SLN iden-
tification in 22 patients using 99mTc sulfur colloid.7 Giulia-
no et al first described intraoperative SLN detection using
blue dye in 174 patients, with a 66% SLN identification rate
and 12% false-negative rate.13 A combination of blue dye and
radiocolloid scan may yield better results. Albertini et al used
a combination of the two techniques and reported a 92%
success rate in 62 breast cancer patients.16 Many authors have
reported increased accuracy using the double technique (dye
and radiocolloid).16,17 However, in a randomized trial, Mor-
row et al showed no difference in the rate of SLN identifica-
tion when using blue dye alone or in combination with the
radiocolloid technique.18 SLN identification has an initial
learning curve.12,13,18 In the present series, during the latter
half of the study, the SLN identification rate reached 96%.
The overall SLN identification rate of 90.8% using blue dye
alone is comparable to those with the combination method
in the literature. The learning curve of SLN using blue dye is
small and surgeons doing routine breast surgery can easily
master the dye method by performing 20–25 cases.
The overall sensitivity of the SLN in predicting axillary
node status in the current study was relatively low (84.2%),
although specificity was 100% and accuracy was 91.3%. The
negative predictive value of SLNB for axillary lymph node sta-
tus was 83.8%. The reported rates of sensitivity and specificity
Table. Results of sentinel lymph node biopsy (SLNB) and axillary
lymph node status on histopathological examination
Axillary lymph node status
Positive Negative
SLNB
   Positive 32 10
   Negative 16 31
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for SLNB range from 66% to 100% in the literature.9,13 The
reasons for low sensitivity include previous excisional biop-
sy, multicentric tumour, heavy nodal disease and large tumour
size.19,20 The low sensitivity in the current study could be ex-
plained by the patient profiles. In two of six patients with Tx
lesions, one of three patients with multicentric tumours, and
all three patients with heavy nodal disease, the SLN was falsely
negative and could not predict axillary status accurately.
The second issue to be addressed is the role of SLNB in
LABC. The inherent problems of LABC are large tumour size,
prior chemotherapy and heavy nodal disease leading to altered
lymphatic pathways. However, recent studies indicate that the
SLN can be identified accurately despite the large tumour size
and prior chemotherapy.10,11,21,22 In the present study, the
SLN was identified in 11 of 15 LABC patients (73.3%), and the
false-negative rate was 9.1%. Stearns et al report an SLN iden-
tification rate of 85% with a false-negative rate of 14% in 34
patients with LABC after neoadjuvant chemotherapy.11 Sim-
ilarly, Cohen et al reported an 82% identification rate and
a 12% false-negative rate in 38 patients after neoadjuvant
chemotherapy.22 In the current study, the number of patients
in this subgroup was too small to allow a definitive conclu-
sion. The role of SLNB in LABC patients, especially after
neoadjuvant chemotherapy, remains investigational.
The third issue that was evaluated in the present study
was intraoperative assessment of SLNB. Traditionally, frozen-
section analysis is considered the method of choice for intra-
operative assessment.9,23,24 However, these facilities are not
widely available in many centres in developing countries, and
the accuracy of frozen section varies from 78% to 95%, with a
false-negative rate of 6–24%.9,23,24 In addition, the frozen-
section method is associated with 25–50% tissue loss and
freezing artefacts.23,24
IIC is emerging as an alternative to frozen section, with
promising results. Rubio et al first reported experience with
IIC in SLN assessment in breast cancer patients with 88.2%
sensitivity and 100% specificity.25 Motomura et al reported
sensitivity, specificity and accuracy of 96.7%, 91.9% and 92.8%,
respectively, using IIC for SLN assessment in 101 breast cancer
patients.26 Recently, however, Shiver et al and Lee at al re-
ported relatively low sensitivities (56% and 65%) using IIC for
SLN assessment.27,28 The specificity of IIC was 100% in both
studies. In comparison, the sensitivity and specificity of IIC in
the present study were 96.9% and 100%, resulting in a high
accuracy of 98.6%. IIC was preferred over frozen section be-
cause it is less expensive, technically easy and does not require
additional infrastructure.27
Conclusions
These results show that a high SLNB detection rate can be
achieved using the blue-dye method alone. The role of SLNB
in LABC patients, especially after neoadjuvant chemotherapy,
remains investigational. The overall results of IIC are very
promising, and we feel that it should be used as an alternative
to frozen section in view of its simplicity, low cost and high
accuracy.
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